Page 11 - EndoProxy2012_final

endo | 100 Endo Boulevard | Chadds Ford, Pennsylvania 19317 5
DAVID P. HOLVECK is President, Chief Executive Officer and a Director of Endo. Prior to joining
Endo in April 2008, Mr. Holveck was President of Johnson & Johnson Development Corpora-
tion and Vice President, Corporate Development of Johnson & Johnson, a diversified healthcare
company, since 2004. Mr. Holveck joined Johnson & Johnson as a Company Group Chairman in
1999, following the acquisition of Centocor, Inc., a biotechnology company, by Johnson & John-
son. Mr. Holveck was Chief Executive Officer of Centocor, Inc. at the time of the acquisition. Mr.
Holveck joined Centocor in 1983 and progressed through various executive positions. In 1992,
he assumed the role of President and Chief Operating Officer and later that year was named
President and Chief Executive Officer. Prior to joining Centocor, he had held positions at General
Electric Company, Corning Glass Works and Abbott Laboratories. Mr. Holveck is a member of
the Board of Trustees for The Fund for West Chester University, as well as the Board of Direc-
tors of the Pharmaceutical Research & Manufacturers of America (PhRMA), the University City
Science Center and the Kimmel Center. Mr. Holveck’s knowledge of the Company, its operations
and the evolving healthcare environment is valuable to the Board of Directors in evaluating and
directing the Company’s future. Through his service on the boards of directors of other organi-
zations as well as his prior senior executive positions at global pharmaceutical and healthcare
product companies, Mr. Holveck has developed extensive knowledge of operational leadership,
risk oversight and management, as well as the pharmaceutical and device industries.
NANCY J. HUTSON, Ph.D. has been a member of the Board of Directors since 2009 and is a
member of Endo’s Compensation Committee, Nominating & Governance Committee and Trans-
actions Committee. Dr. Hutson retired from Pfizer, Inc. in 2006 after spending 25 years in vari-
ous research and leadership positions, most recently serving as Senior Vice President, Pfizer
Global Research and Development and Director of Pfizer’s pharmaceutical R&D site, known as
Groton/New London Laboratories, the largest R&D site of any pharmaceutical company. At Pfiz-
er, she led 4,500 colleagues (primarily scientists) and managed a budget in excess of $1 billion.
She currently is a director of Cubist Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.,
and serves on the board of Planned Parenthood of Connecticut. Dr. Hutson owns and operates
Standing Stones Farm in Ledyard, CT which is dedicated to supporting the equestrian sport of
dressage. Having 25 years of experience with Pfizer’s Research and Development organization,
Dr. Hutson brings to the Board valuable pharmaceutical discovery research abilities, scientific
expertise and an immense knowledge of the pharmaceutical industry. Her years of senior execu-
tive experience also bring a strong skill set to our Board regarding operational leadership and
evaluation of business strategy.
MICHAEL HYATT is currently a Director of Endo and is Chairman of Endo’s Transactions Com-
mittee and a member of Endo’s Nominating & Governance Committee. Mr. Hyatt had been a
director of Algos Pharmaceutical Corporation since November 1996 and became a director of
Endo following its merger with Algos in July 2000. Mr. Hyatt is currently a senior advisor to
Irving Place Capital, a leading institutional private equity firm focused on making equity invest-
ments in middle-market companies. Until 2008, Mr. Hyatt was a Senior Managing Director of
Bear Stearns & Co., Inc. In April 2009, Mr. Hyatt was appointed a director of Schiff Nutrition
International, Inc., a publicly traded manufacturer and marketer of nutritional supplements.
Through Mr. Hyatt’s experiences as a senior investment professional, manager and advisor, he
has gained expertise in evaluating business strategies, conducting financial analysis and ana-
lyzing companies’ future prospects. His career experience makes him a skilled advisor who pro-
vides critical insight into financial matters.
JOHN J. DELUCCA has been a member of the Board of Directors since 2006 and is the Chair-
man of Endo’s Audit Committee and is a member of Endo’s Compensation Committee. Mr. De-
lucca was Executive Vice President and Chief Financial Officer of the REL Consultancy Group, a
business consulting firm, until his retirement in 2004. Prior to that, he served as Chief Financial
Officer and Executive Vice President, Finance & Administration, of Coty, Inc., a fragrance and
beauty products company, from 1999 to 2002. From 1993 to 1999, he was Senior Vice President
and Treasurer of RJR Nabisco, Inc. During his career, he also served in executive positions for
Hascoe Associates, Inc., The Lexington Group, the Trump Group, International Controls Corp.,
and Textron, Inc. Mr. Delucca is currently a Non-Executive Director and chairs the Audit Com-
mittee of The Elliot Company, an industrial manufacturer. Mr. Delucca also serves as a Non-
Executive Director and chairs the Audit Committee and is a member of the Compensation Com-
mittee of Elster Group, a publicly traded company providing integrated metering and utilization
solutions to the gas, electricity and water industries. Through his senior executive roles and
financial experience at various organizations, Mr. Delucca has expertise in financial analysis,
financial statements, evaluation of business strategies, and contributes to the Board valuable
leadership and risk management skills. Mr. Delucca also has extensive corporate governance
experience from his services, both current and historical, on other company boards.